Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-3

CD28/B7 SYSTEM OF T CELL COSTIMULATION

Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717

LAG-3, a novel lymphocyte activation gene closely related to CD4.

Triebel, F., Jitsukawa, S., Baixerás, E., Roman‐Roman, S., Genevée, C., Viégas-Pèquignot, E., & Hercend, T. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.171.5.1393 · Cited by 936

Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.

Baixerás, E., Huard, B., Miossec, C., Jitsukawa, S., Martin, M., Hercend, T., Auffray, C., Triebel, F., & Piatier‐Tonneau, D. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.2.327 · Cited by 397

CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteins

Huard, B., Prigent, P., Tournier, M., Bruniquel, D., & Triebel, F. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250949 · Cited by 391

Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor: evidence for more than one receptor class.

Gronwald, R. G., Grant, F. J., Haldeman, B. A., Hart, C. E., O’Hara, P. J., Hagen, F. S., Ross, R., Bowen‐Pope, D. F., & Murray, M. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.10.3435 · Cited by 316

Characterization of the major histocompatibility complex class II binding site on LAG-3 protein

Huard, B., Mastrangeli, R., Prigent, P., Bruniquel, D., Donini, S., Tayar, N. E., Maigret, B., Dréano, M., & Triebel, F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5744 · Cited by 308

CD3/TCR complex‐associated lymphocyte activation gene‐3 molecules inhibit CD3/TCR signaling

Hannier, S., Tournier, M., Bismuth, G., & Triebel, F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.4058 · Cited by 248

Peroxisome proliferator-activated receptor γ activators affect the maturation of human monocyte-derived dendritic cells

Gosset, P., Charbonnier, A.-S., Delerive, P., Fontaine, J., Staels, B., Pestel, J., Tonnel, A., & Trottein, F. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(2001010)31:10 · Cited by 225

Retroviral-Mediated Transfer of the Green Fluorescent Protein Gene Into Murine Hematopoietic Cells Facilitates Scoring and Selection of Transduced Progenitors In Vitro and Identification of Genetically Modified Cells In Vivo

Persons, D. A., Allay, J. A., Allay, E. R., Smeyne, R. J., Ashmun, R. A., Sorrentino, B. P., & Nienhuis, A. W. (1997) · Blood · doi:10.1182/blood.v90.5.1777 · Cited by 222

Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand

Huard, B., Gaulard, P., Faure, F., Hercend, T., & Triebel, F. (1994) · Immunogenetics · doi:10.1007/bf00241263 · Cited by 202

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors

Franzese, O., Torino, F., Fuggetta, M. P., Aquino, A., Roselli, M., Bonmassar, E., Giuliani, A., & D’Atri, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16335 · Cited by 23

Effects of Salmonella on spatial-temporal processes of jejunal development in chickens

Schokker, D., Smits, M. A., Hoekman, A. J. W., Parmentier, H. K., & Rebel, J. M. J. (2010) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2010.05.013 · Cited by 22

A molecule in teleost fish, related with human MHC-encoded G6F, has a cytoplasmic tail with ITAM and marks the surface of thrombocytes and in some fishes also of erythrocytes

Ohashi, K., Takizawa, F., Tokumaru, N., Nakayasu, C., Toda, H., Fischer, U., Moritomo, T., Hashimoto, K., Nakanishi, T., & Dijkstra, J. M. (2010) · Immunogenetics · doi:10.1007/s00251-010-0460-1 · Cited by 22

Inhibiting the Unconventionals: Importance of Immune Checkpoint Receptors in γδ T, MAIT, and NKT Cells

Tardos, E. C., Baglioni, M. V., & Bekiaris, V. (2021) · Cancers · doi:10.3390/cancers13184647 · Cited by 20

Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses

Zettl, M., Wurm, M., Schaaf, O., Mostböck, S., Tirapu, I., Apfler, I., Lorenz, I. C., Frego, L., Kenny, C. H., Thibodeau, M. S., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2080328 · Cited by 21

Lymphocyte Activation Gene-3 Expression Defines a Discrete Subset of HIV-Specific CD8 + T Cells That Is Associated with Lower Viral Load

Peña, J., Jones, N. G., Bousheri, S., Bangsberg, D. R., & Cao, H. (2013) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2012.0195 · Cited by 23

Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules

D’Arrigo, P., Tufano, M., Rea, A., Vigorito, V., Novizio, N., Russo, S., Romano, M. F., & Romano, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181106114421 · Cited by 21

A molecular signature for CD8 + T cells from visceral leishmaniasis patients

Singh, B., Chauhan, S. B., Kumar, R., Singh, S. S., Ng, S. S., Amante, F. H., Rivera, F. D. L., Singh, O. P., Rai, M., Nylén, S., et al. (2019) · Parasite Immunology · doi:10.1111/pim.12669 · Cited by 21

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?

Krzyżanowska, N., Wojas‐Krawczyk, K., Milanowski, J., & Krawczyk, P. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063087 · Cited by 19

Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors

Davar, D., & Zarour, H. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_2 · Cited by 20

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas

Witkowska, M., & Smolewski, P. (2018) · Journal of Immunology Research · doi:10.1155/2018/1982423 · Cited by 19

The ligand-dependent suppression of TCR signaling by the immune checkpoint receptor LAG3 depends on the cytoplasmic RRFSALE motif

Radakovics, K., Linhares, A. D. S., Salzer, B., Lehner, M., Izadi, S., Castilho, A., Pickl, W. F., Leitner, J. M., & Steinberger, P. (2023) · Science Signaling · doi:10.1126/scisignal.adg2610 · Cited by 19

Unexpected role for MHC II–peptide complexes in shaping CD8 T-cell expansion and differentiation in vivo

Do, J., Valujskikh, A., Vignali, D. A. A., Fairchild, R. L., & Min, B. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207219109 · Cited by 19

CAR-T Cells Targeting Immune Checkpoint Pathway Players

Golubovskaya, V. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2704121 · Cited by 19

LAG3 in gastric cancer: it’s complicated

Ulase, D., Behrens, H., Krüger, S., Heckl, S. M., Ebert, U., Becker, T., & Röcken, C. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04954-1 · Cited by 19

The molecular landscape of T cell exhaustion in the tumor microenvironment and reinvigoration strategies

Heidari‐Foroozan, M., Rezalotfi, A., & Rezaei, N. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2401352 · Cited by 19

Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints

Dulal, D., Boring, A. R., Terrero, D., Johnson, T. L., Tiwari, A. K., & Raman, D. (2023) · Cancers · doi:10.3390/cancers15102774 · Cited by 20

Immunotherapy and biomarkers in patients with lung cancer with tuberculosis: Recent advances and future Directions

Yang, L., Li, Z., Ye, Z., Li, L., Guan, J., & Gong, W. (2023) · iScience · doi:10.1016/j.isci.2023.107881 · Cited by 18

Advances in new targets for immunotherapy of small cell lung cancer

Zheng, Z., Liu, J., Ma, J., Kang, R., Liu, Z., & Yu, J. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15178 · Cited by 18

Checkpoint Inhibitors in Dogs: Are We There Yet?

Giuliano, A., Pimentel, P. A. B., & Horta, R. D. S. (2024) · Cancers · doi:10.3390/cancers16112003 · Cited by 19

Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements

Martínez‐Pérez, A., Granda‐Díaz, R., Aguilar-García, C., Sordo‐Bahamonde, C., & Gonzalez, S. R. (2024) · Biomarker Research · doi:10.1186/s40364-024-00671-0 · Cited by 20

Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer

Khadela, A. D., Chavda, V. P., Postwala, H. I., Ephraim, R., Apostolopoulos, V., & Shah, Y. B. (2023) · Cancers · doi:10.3390/cancers15020543 · Cited by 18

Integration of single sample and population analysis for understanding immune evasion mechanisms of lung cancer

Li, X., Xu, M. J., Chen, H., Fu, X., Wang, P., Chen, X., Gu, C., & Zhou, J. (2023) · npj Systems Biology and Applications · doi:10.1038/s41540-023-00267-8 · Cited by 17

Regulation of Cancer Immune Checkpoint: Mono- and Poly-Ubiquitination: Tags for Fate

Yao, H., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_13 · Cited by 17

Molecular cloning of bovine lymphocyte activation gene-3 and its expression characteristics in bovine leukemia virus-infected cattle

Shirai, T., Konnai, S., Ikebuchi, R., Okagawa, T., Suzuki, S., Sunden, Y., Onuma, M., Murata, S., & Ohashi, K. (2011) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2011.08.018 · Cited by 17

Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape

Inocencio, J. F., Mitrasinovic, S., Asad, M., Parney, I. F., Zang, X., & Himes, B. T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424396 · Cited by 18

Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies

Polania, J. W., Lerner, E., Wilkinson, D. S., Hoyt-Miggelbrink, A. M., & Fecci, P. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.777073 · Cited by 17

Plasticity and Rigidity in Adaptor Protein-2-Mediated Internalization of the TCR:CD3 Complex

Szymczak-Workman, A. L., & Vignali, D. A. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.4153 · Cited by 16

LAG Time in the Era of Immunotherapy—New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene‐3

Luca, V. C. (2025) · Immunological Reviews · doi:10.1111/imr.70002 · Cited by 15

Therapeutic potential of targeting LAG-3 in cancer

Davar, D., Anderson, A. C., & Díaz-Padilla, I. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011652 · Cited by 17

Lymphocyte-activation gene 3 (LAG-3) as a promising immune checkpoint in cancer immunotherapy: From biology to the clinic

Alqurashi, Y. E. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155124 · Cited by 15

Advances in understanding the role of immune checkpoint LAG-3 in tumor immunity: a comprehensive review

Luo, Y., Cai, X., Yang, B., Lu, F., Cheng, Y., & Wu, G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1402837 · Cited by 14

Harnessing NK Cell Checkpoint-Modulating Immunotherapies

Chauhan, S. K. S., Koehl, U., & Kloeß, S. (2020) · Cancers · doi:10.3390/cancers12071807 · Cited by 15

The DNA damage repair-related gene PKMYT1 is a potential biomarker in various malignancies

Shao, C., Wang, Y., Pan, M., Guo, K. X., Molnar, T. F., Kocher, F., Seeber, A., Barr, M. P., Navarro, A., Han, J., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-973 · Cited by 13

Exploring new frontiers in LAG-3 biology and therapeutics

Wang, J., Klein, C., Cochran, J. R., Sockolosky, J. T., & Lippow, S. M. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.05.008 · Cited by 13

Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment

Capitani, N., Patrussi, L., & Baldari, C. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011221 · Cited by 15

Role of lymphocytes, macrophages and immune receptors in suppression of tumor immunity

Singh, A., Anang, V., Kumari, K., Kottarath, S. K., & Verma, C. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.10.002 · Cited by 14

A LAG3-interfering oligonucleotide acts as an adjuvant to enhance the antibody responses induced by recombinant protein vaccines and inactivated influenza virus vaccines

Li, Z., Song, Y., Cui, C., Lan, Y., Li, X., Liu, Y., Lu, F., Zhang, Y., Yu, Y., & Wang, L. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-09919-4 · Cited by 13

A capsular polysaccharide from a healthy human microbiota member activates a Lag-3-NK cell axis to restrain colon cancer and augment immunotherapy

Weis, A. M., Bauer, K. M., Tang, W. W., Victor, E. S., Bell, R. S., Brown, D. G., Ekiz, H. A., Tran, V., Klag, K. A., Swanson, E. A., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116172 · Cited by 14

Post-translational modifications of immune checkpoints: molecular mechanisms, tumor microenvironment remodeling, and therapeutic implications

Hsieh, H.-C., Ling, L.-L., & Yi-Ching, W. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-025-01202-1 · Cited by 17

Implications of Rectal Cancer Radiotherapy on the Immune Microenvironment: Allies and Foes to Therapy Resistance and Patients’ Outcome

Sartorius, D., Blume, M. L., Fleischer, J. R., Ghadimi, M. B., Conradi, L., & Oliveira, T. D. (2023) · Cancers · doi:10.3390/cancers15215124 · Cited by 11

Surface Immune Checkpoints as Potential Biomarkers in Physiological Pregnancy and Recurrent Pregnancy Loss

Zych, M., Kniotek, M., Roszczyk, A., Dabrowski, F. A., Jędra, R., & Zagożdżon, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179378 · Cited by 12

LAG ‐3—An incompletely understood target in cancer therapy

Leitner, J. M., Radakovics, K., & Steinberger, P. (2024) · The FASEB Journal · doi:10.1096/fj.202401639r · Cited by 12

Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials

Ren, K., Hamdy, H., Meyiah, A., & Elkord, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1501613 · Cited by 12

The Immune Checkpoint Inhibitor LAG-3 and Its Ligand GAL-3 in Vulvar Squamous Neoplasia

Cocks, M. M., & Mills, A. M. (2021) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000782 · Cited by 14

LAG3 disrupts the TCR signal by local acidification

Hivroz, C. (2022) · Nature Immunology · doi:10.1038/s41590-022-01196-0 · Cited by 12

The Features of Checkpoint Receptor—Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition

Kuzevanova, A. Y., Апанович, Н. В., Mansorunov, D., Коротаева, А. А., & Karpukhin, A. V. (2022) · Biomedicines · doi:10.3390/biomedicines10092081 · Cited by 12

Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer

Muaibati, M., Abasi, A., Zhang, T., Dai, Y., Li, R., Huang, F., Li, K., Tong, Q., Huang, X., & Zhuang, L. (2023) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2023.3 · Cited by 13

Molecular cloning and expression analysis of pig lymphocyte activation gene-3 (LAG-3; CD223)

Kim, S.-S., Kim, S. H., Kang, H.-S., Chung, H. Y., Choi, I., Cheon, Y., Lee, K., Lee, D.-M., Park, J., Lee, S. Y., et al. (2009) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2009.07.001 · Cited by 12

Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives

Compagno, S., Casadio, C., Galvani, L., Rosellini, M., Marchetti, A., Tassinari, E., Piazza, P., Mottaran, A., Santoni, M., Schiavina, R., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195738 · Cited by 11

The Role of YY1 in the Regulation of LAG-3 Expression in CD8 T Cells and Immune Evasion in Cancer: Therapeutic Implications

Merenstein, A., Obeidat, L., Zaravinos, A., & Bonavida, B. (2024) · Cancers · doi:10.3390/cancers17010019 · Cited by 11

Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects

Nsingwane, Z., Candy, G. P., Devar, J. W., Omoshoro–Jones, J., Smith, M., & Nweke, E. E. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05648-4 · Cited by 13

The study of immune checkpoint inhibitors in chronic hepatitis B virus infection

Li, S., Li, N., Yang, S., Deng, H., Li, Y., Wang, Y., Jiaqiang, Y., Lv, J., Dong, L., Yu, G., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108842 · Cited by 11

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature

Yadav, R., Hakobyan, N., & Wang, J. C. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512502 · Cited by 10

Resistance to anti-LAG-3 plus anti-PD-1 therapy in head and neck cancer is mediated by Sox9+ tumor cells interaction with Fpr1+ neutrophils

Wang, X., Cheng, M., Chen, S., Zhang, C., Ling, R., Qiu, S., Chen, K., Zhou, B., Li, Q., Lei, W., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59050-4 · Cited by 11

The inhibitory receptor LAG3 affects NK cell IFN-γ production through glycolysis and the PSAT1/STAT1/IFNG pathway

Ge, H., Guo, N., Liu, Y., Lang, B., Yin, X., Yu, X., Zhang, Z., Fu, Y., Ding, H., Hu, Q., et al. (2025) · mBio · doi:10.1128/mbio.00230-25 · Cited by 10

Negative Immune Checkpoint Inhibitors

Drewniak‐Świtalska, M., Fortuna, P., & Krzystek‐Korpacka, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060713 · Cited by 10

Dampening antiviral immunity can protect the host

Panetti, C., Kao, K., & Joller, N. (2021) · FEBS Journal · doi:10.1111/febs.15756 · Cited by 10

LAG-3 is a promising inhibitory immune checkpoint for antitumor immunotherapy

Tian, J. S., Liu, Y., Zhang, T., Yue, L., Xiao, Y., & Guo, C. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2039124 · Cited by 10

Immune checkpoint molecules beyond PD-1 and CTLA-4: emerging targets in autoimmune diseases and cancer immunotherapy

Dadfar, S., Eivazzadeh, Y., Molavi, H., Abedi, H., Razavi, F. T., & Haghmorad, D. (2026) · Inflammation Research · doi:10.1007/s00011-026-02211-y · Cited by 9

LAG-3 Contribution to T Cell Downmodulation during Acute Respiratory Viral Infections

Rodríguez‐Guilarte, L., Ramírez, M. A., Andrade, C. A., & Kalergis, A. M. (2023) · Viruses · doi:10.3390/v15010147 · Cited by 11

Double Guard Efficiency and Safety—Overcoming Resistance to Immunotherapy by Blocking or Stimulating Several Immune Checkpoints in Non-Small Cell Lung Cancer Patients

Kalinka‐Warzocha, E., Wojas‐Krawczyk, K., & Krawczyk, P. A. (2023) · Cancers · doi:10.3390/cancers15133499 · Cited by 9

CD4 and LAG-3 from sharks to humans: related molecules with motifs for opposing functions

Takizawa, F., Hashimoto, K., Miyazawa, R., Ohta, Y., Veríssimo, A., Flajnik, M. F., Parra, D., Tokunaga, K., Suetake, H., Sunyer, J. O., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1267743 · Cited by 8

The correlation between LAG-3 expression and the efficacy of chemoimmunotherapy in advanced biliary tract cancer

Tang, C., Lin, Y., Yeh, Y., Chung, S., Chang, Y., Hung, Y., Chen, S., Chen, M., & Chiang, N. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03878-0 · Cited by 8

Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy

Abdkarimi, S., Soofiyani, S. R., Elham, G., Abdolahi, H. M., Safarzadeh, E., & Baradaran, B. (2020) · European Journal of Cancer Care · doi:10.1111/ecc.13268 · Cited by 9

Advances in Therapies Targeting Inhibitory Checkpoint Receptors: TIGIT, LAG-3, and Beyond

Healy, J. A., Han, J., Bauché, D., Keenan, T. E., Casasnovas-Nieves, J., & Dobrenkov, K. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061521-093717 · Cited by 7

Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families

Liu, R., Jiang, X., Dong, R., Zhang, Y., Gai, C., & Peng, W. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1499663 · Cited by 7

Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents

Pérez-Santos, M., Anaya-Ruı́z, M., Villafaña-Díaz, L., & Sánchez-Esgua, G. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2148652 · Cited by 7

Bibliometric analysis of evolutionary trajectory and prospective directions of LAG-3 in cancer

Wang, J., Wang, S., Zhang, Y., & Zhang, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1329775 · Cited by 7

Dissociation of LAG-3 inhibitory cluster from TCR microcluster by immune checkpoint blockade

Hashimoto, A. S., Bowman, E. P., Sakuma, M., Yoneda, N., Yugi, K., Malefyt, R. D. W., & Saito, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444424 · Cited by 7

Predicting protein interactions of the kinase Lck critical to T cell modulation

Gao, M., & Skolnick, J. (2024) · Structure · doi:10.1016/j.str.2024.09.010 · Cited by 8

The frequency and dynamics of CD4+ mucosal‐associated invariant T (MAIT) cells in active pulmonary tuberculosis

Xiong, K., Sun, W., Wang, H., Xie, J., Su, B., & Fan, L. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104381 · Cited by 8

Global Screening of LUBAC and OTULIN Interacting Proteins by Human Proteome Microarray

Zhou, L., Ge, Y., Fu, Y., Wu, B., Zhang, Y., Li, L., Cui, C., Wang, S., & Zhang, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.686395 · Cited by 7

Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer?

Zhang, X., He, Y., Jia, K., Dziadziuszko, R., Zhao, S., Deng, J., Wang, H., Hirsch, F. R., & Zhou, C. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.09.20 · Cited by 7

Cytokines and Metabolic Factors Regulate Tumoricidal T-Cell Function During Cancer Immunotherapy

Adler, A. J., Mittal, P., Ryan, J. M., Zhou, B., Wasser, J. S., & Vella, A. T. (2016) · Immunotherapy · doi:10.2217/imt-2016-0097 · Cited by 6

The emerging role of lymphocyte‐activation gene 3 targeting in the treatment of solid malignancies

Giri, V. K., McDermott, D. F., & Zaemes, J. P. (2025) · Cancer · doi:10.1002/cncr.35892 · Cited by 6

Multomic analysis reveals the potential of LAG3 as a prognostic and immune biomarker and its validation in osteosarcoma

Cao, Q., Zhang, Y., Cheng, C., Wang, X., Fan, P., Huang, J., & Dai, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-10290-w · Cited by 6

Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma

Re, V. D., Repetto, O., Mussolin, L., Brisotto, G., Elia, C., Lopci, E., dʼAmore, E. S. G., Burnelli, R., & Mascarin, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.965803 · Cited by 5

Co-inhibitory receptors, transcription factors and tolerance

Mohammadzadeh, A. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106572 · Cited by 6

Therapeutic cancer vaccines

Berinstein, N. L., & Berinstein, J. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00045-8 · Cited by 6

Overcoming chimeric antigen receptor-T (CAR-T) resistance with checkpoint inhibitors: Existing methods, challenges, clinical success, and future prospects : A comprehensive review

Tulsian, K., Thakker, D., & Vyas, V. K. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141364 · Cited by 5

Immune Checkpoint Inhibitors

Kaliński, P., & Basse, P. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00001-9 · Cited by 6

From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy for autoimmune diseases

Zhou, X., Gu, Y., Wang, H., Zhou, W., Zou, L., Li, S., Hua, C., & Gao, S. (2023) · Inflammation Research · doi:10.1007/s00011-023-01742-y · Cited by 5

A combined analysis of multi-omics data reveals the prognostic values and immunotherapy response of LAG3 in human cancers

Peng, J., Du, Z., Sun, Y., & Zhou, Z. (2023) · European journal of medical research · doi:10.1186/s40001-023-01583-9 · Cited by 5

A reporter gene assay for measuring the bioactivity of anti‐LAG‐3 therapeutic antibodies

Wang, L., Yu, C., Wang, K., & Wang, J. (2020) · Luminescence · doi:10.1002/bio.3905 · Cited by 5

Mutational and immunologic Landscape in malignant Salivary Gland Tumors harbor the potential for novel therapeutic strategies

Witte, H. M., Gebauer, N., & Steinestel, K. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103592 · Cited by 5

Immune checkpoints and their promising prospect in cholangiocarcinoma treatment in combination with other therapeutic approaches

Vatankhah, F., Salimi, N., Khalaji, A., & Baradaran, B. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109526 · Cited by 5

Cancer Immunotherapy Targeting Co-signal Molecules

Nakajima, M., & Tamada, K. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_11 · Cited by 5

TIGIT: Will it be the next star therapeutic target like PD-1 in hematological malignancies?

Liu, Y., Liu, W., & Wu, T. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104495 · Cited by 4

Pan-cancer and single-cell analysis reveal dual roles of lymphocyte activation gene-3 (LAG3) in cancer immunity and prognosis

Wang, Y., Zhao, Y., Zhang, G., Lin, Y., Fan, C., Wei, H., Chen, S., Guan, L., Liu, K., Yu, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-74808-4 · Cited by 4

Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy

Hosseininejad-Chafi, M., Eftekhari, Z., Oghalaie, A., Behdani, M., Sotoudeh, N., & Kazemi‐Lomedasht, F. (2024) · Medical Oncology · doi:10.1007/s12032-024-02588-y · Cited by 4

Targeting LAG-3: Relatlimab, Fianlimab, and ieramilimab reshape the landscape of cancer combination immunotherapy

Ghasemi, K. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156163 · Cited by 4

Characterization of 405B8H3 ( D‐E ), a newly engineered high affinity chimeric LAG ‐3 antibody with potent antitumor activity

Lan, X., Yang, T. T. C., Wang, Y., Qu, B., Rong, S., & Song, N. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13648 · Cited by 4

Ubiquitination of Major Histocompatibility Complex II Changes Its Immunological Recognition Structure

Kozono, Y., Kuramochi, M., Sasaki, Y. C., & Kozono, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242317083 · Cited by 4

Monoclonal Antibody against Porcine LAG3 Inhibits Porcine Reproductive and Respiratory Syndrome Virus Infection

Wang, H., Zheng, X., Zheng, D., Wang, X., Zhao, Z.-Q., Zhao, M., Guo, Q., & Mu, Y. (2024) · Veterinary Sciences · doi:10.3390/vetsci11100483 · Cited by 4

CpG-ODN Facilitates Effective Intratracheal Immunization and Recall of Memory against Neoantigen-Expressing Alveolar Cells

Riehn, M., Cebula, M., Häuser, H., & Wirth, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01201 · Cited by 4

Phosphorylation: A Fast Switch For Checkpoint Signaling

Wang, Y., Wang, P., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_15 · Cited by 4

Nanotechnology and Immunomodulators in Cancer

Volovat, C. D., Volovăț, S. R., & Agop, M. (2022) · Springer eBooks · doi:10.1007/978-981-16-6379-6_5 · Cited by 4

Development and validation of a GRGPI model for predicting the prognostic and treatment outcomes in head and neck squamous cell carcinoma

Han, F., Wang, H., Chang, M., Hu, Y., Liang, L., Li, S., Liu, F., He, P. F., Yang, X., & Li, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.972215 · Cited by 4

WNT5A transforms intestinal CD8αα+ IELs into an unconventional phenotype with pro-inflammatory features

Zhao, D., Xu, A., Dai, Z., Peng, J.-C., Zhu, M., Shen, J., Zheng, Q., & Ran, Z. (2015) · BMC Gastroenterology · doi:10.1186/s12876-015-0402-3 · Cited by 4

The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells

Workman, C. J., & Vignali, D. A. A. (2003) · European Journal of Immunology · doi:10.1002/eji.200323382 · Cited by 318

LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination

Triebel, F. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.10.001 · Cited by 150

The negative regulatory function of the lymphocyte‐activation gene‐3 co‐receptor (CD223) on human T cells

Maçon‐Lemaître, L., & Triebel, F. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02145.x · Cited by 190

Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)

Workman, C. J., & Vignali, D. A. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.688 · Cited by 344

Biochemical Analysis of the Regulatory T Cell Protein Lymphocyte Activation Gene-3 (LAG-3; CD223)

Li, N., Workman, C. J., Martin, S., & Vignali, D. A. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6806 · Cited by 139